Systemic Miltefosine as an Adjunct Treatment of Progressive Acanthamoeba Keratitis

Ocul Immunol Inflamm. 2021 Nov 17;29(7-8):1576-1584. doi: 10.1080/09273948.2020.1758156. Epub 2020 May 29.

Abstract

Purpose: To report our experience with oral miltefosine (MLT) as an adjunct treatment for progressive Acanthamoeba keratitis (AK).Methods: Retrospective case series of all patients who underwent treatment with oral MLT for AK at Bascom Palmer Eye Institute from 2017 to 2020.Results: Six females from 16 to 55 years old, with a microbiologic diagnosis of Acanthamoeba, were treated with MLT and standard medical treatment. Four of the six cases deteriorated after initiating treatment and three required a therapeutic keratoplasty. Two patients improved after 1 week of MLT and optical penetrating keratoplasty was performed after clinical resolution. Microbiologic culture of corneal buttons was negative in all cases. All corneal grafts remain clear at last follow-up with best-corrected visual acuity of 20/40 or better.Conclusion: Oral MLT may be a viable adjunctive therapy for recalcitrant AK; however, its use may be associated with a severe inflammatory reaction. Further studies are needed to evaluate its efficacy and variable clinical response.

Keywords: Acanthamoeba; Cornea; impavido; infectious keratitis; miltefosine.

Publication types

  • Case Reports

MeSH terms

  • Acanthamoeba Keratitis / diagnosis
  • Acanthamoeba Keratitis / drug therapy*
  • Acanthamoeba Keratitis / etiology
  • Administration, Oral
  • Adolescent
  • Adult
  • Antiprotozoal Agents / therapeutic use*
  • Contact Lenses / adverse effects
  • Female
  • Follow-Up Studies
  • Humans
  • Keratoplasty, Penetrating
  • Middle Aged
  • Phosphorylcholine / analogs & derivatives*
  • Phosphorylcholine / therapeutic use
  • Retrospective Studies
  • Risk Factors
  • Visual Acuity / physiology
  • Young Adult

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine